Cabergoline in prolactinomas

References

• Molitch ME, Thorner MO, Wilson C. Therapeutic controversy: management of prolactinomas. J Clin Endocrinol Metab 1997;82(4):996–1000.
   Google Scholar
• Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13(2):220–240.
   PubMed Web of Science ®Google Scholar
• Vance ML, Evans WS, Thorner MO. Diagnosis and treatment (Drugs five years later): bromocriptine. Ann Intern Med 1985;100:78–79.
   Google Scholar
• Bevan JS, Davis JRE. Cabergoline: an advance in dopaminergic therapy.
   Google Scholar
• Biller BMK, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81(6):2338–2343.
   PubMedGoogle Scholar
• Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996;51(6):954–965.
   Google Scholar
• Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82(II):3574–3579.
   Google Scholar
• Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876–883.
   PubMed Web of Science ®Google Scholar
• Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinomas with cabergoline: a study of 85 patients. Clin Endocrinol Oxf 1997; 46(4)409–413.
   Google Scholar
• Rains CP, Bryson HM, Fitton A. Cabergoline: a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition of lactation. Drugs 1995;49(2):255–279.
   Google Scholar
• Vigneron PV, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 1995;24(16):753–757 (abstract).
   Google Scholar
• Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (for the Cabergoline Comparative Study Group). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904–909.
   Google Scholar
• Webster J. A comparative review of the tolerability profile of dopamine agonists in the treatment of hyperprolactinemia and inhibition of lactation. Drug Saf 1996;14(4):228–238.
   Google Scholar
• Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988;36:67–82.
   PubMed Web of Science ®Google Scholar
• Serri 0. Progress in the management of hyperprolactinemia. N Engl J Med 1994;331: 942–944.
   Google Scholar
• Ferrari C, Barbieri C, Caldara R, et al. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metabol 1989;68:1201–1206.
   PubMed Web of Science ®Google Scholar
• Landolt AM, Vance ML, Reilly PL. Neuro-ophthalmologic findings. In: Landolt AM, Vance ML, Reilly PL, editors. Pituitary Adenomas. London: Churchill Livingston, 1996; 157–175.
   Google Scholar
• Assies J, Verhoeff NPLG, Bosch DA, Hofland U. Intracranial dissemination of a macroprolactinoma. Clin Endocrinol 1993;38:539–546.
   Google Scholar
• Delgrange E, Donckier J. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy (letter). J Clin Endocrinol Metab 1997;82(8):2755–2756.
   Google Scholar
• Colao A, Lombardi G. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy (letter). J Clin Endocrinol Metab 1997;82(8): 2756.
   Google Scholar
• Comabella M, Alvarez-Sabin J, et al. Bromocriptine and postpartum cerebral angiopathy: a causal relationship? Neurology 1996;46(6): 1754–1756.
   Google Scholar
• Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43:2587–2590.
   Google Scholar
• Ferrari C, Paracchi A, Mattei AM, De Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126: 489–494.
   PubMedGoogle Scholar
• Atienza DM, Vigersky RJ, Lack EL, et al. Prolactin-producing pituitary carcinoma with pulmonary metastases. Cancer 1991;68:1605–1610.
   PubMedGoogle Scholar
• Bayindir C, Balak N, Gazioglu N. Prolactin-secreting carcinoma of the pituitary: clinicopathological and immunohistochemical study of a case with intracranial and intraspinal dissemination. Br J Neurosurg 1997; II (4):350–355.
   Google Scholar
• Cohen DL, Diengdoh JV, Thomas DGT, Himsworth RU. An intracranial metastasis from a PRL secreting tumour. Clin Endocrinol 1983;18:259–264.
   Google Scholar
• Gasser RW, Finkenstedt G, Skrabal F, et al. Multiple intracranial metastases from a prolactin secreting pituitary tumour. Clin Endocrinol 1985;22:17–27.
   PubMedGoogle Scholar
• Gollard R, Kosty M, Cheney C, Copeland B, Bordin G. Prolactin-secreting pituitary carcinoma. Cancer 1995;76:1814–1820.
   Google Scholar
• Hurel SJ, Harris PE, McNichol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997;82(9): 2962–2965.
   Google Scholar
• Landgraf R, Rieder G, Schmiedek P, Clados D, Bise K, Von Werder K. Hormone-active intradural spinal metastasis of a prolactinoma - a case report. Klin Wochenschr 1985;63:379–384.
   Google Scholar
• Long MA, Colquhoun IR. Multiple intracranial metastases from a prolactin-secreting pituitary tumor. Clin Radiol 1994;49:356–358.
   Google Scholar
• Martin NA, Hales M, Wilson CB. Cerebellar metastasis from a prolactinoma during treatment with bromocriptine. J Neurosurg 1981;55: 615–619.
   Google Scholar
• Muhr C, Bergstrom M, Lundberg PO, et al. Malignant prolactinoma with multiple intracranial metastases studied with positron emission topography. Neurosurgery 1988;22: 374–379.
   Google Scholar
• O'Brien DP, Phillips JP, Rawluk DR, Farrell MA. Intracranial metastases from pituitary adenoma. Br J Neurosurg 1995;9:211–218.
   Web of Science ®Google Scholar
• Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma. Cancer 1997;79:804–812.
   PubMed Web of Science ®Google Scholar
• Petterson T, MacFarlane IA, MacKenzie JIM, Shaw MDM. Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychiatry 1992;55:1205–1206.
   Google Scholar
• Plangger CA, Twerdy K, Grunert V, Weiser G. Subarachnoid metastases from a prolactinoma. Neurochirurgie 1985;28:235–237.
   Google Scholar
• Popovic EA, Vattuone JR, Siu KH, Busmanis I, Pullar MJ, Dowling J. Malignant prolactinomas. Neurosurgery 1991;29:127–130.
   PubMedGoogle Scholar
• Saeger W, Bosse U, Pfingst E, et al. Prolaktinbildendes Hypophysenkarzi-nom. Pathologe 1995;16:354–358.
   Google Scholar
• Scheithauer BW, Randall RV, Laws ER, Kovacs KT, Horvath E, Whitaker MD. Prolactin cell carcinoma of the pituitary. Cancer 1985;55:598–604.
   PubMedGoogle Scholar
• Walker JD, Grossman A, Anderson JV, et al. Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol 1993; 38:411–419.
   PubMed Web of Science ®Google Scholar
• Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir Wien 1996;138(12):1449–1455 (abstract).
   Google Scholar
• Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T. Analysis of growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir Wien 1995;136(I-2):37-43 (abstract).
   Google Scholar
• Bates AS, Farrell WE, Bicknell EJ, et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997;82:818–824.
   PubMedGoogle Scholar
• Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 199555:1613-1616.
   PubMed Web of Science ®Google Scholar
• Karga HJ, Alexander JIM, Hedley-Whyte ET, Klibanski A, Jameson L. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 1992;74:914–919.
   PubMed Web of Science ®Google Scholar
• Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 1994;78:842–846.
   Google Scholar
• Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38: 765–777.
   Google Scholar
• Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-I antibody. Neurosurgery 1996;38:99–107.
   PubMed Web of Science ®Google Scholar